| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-12446SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB110-89474SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NB100-56726 | |||
| BSA Free | NB100-56722SS | |||
| Azide and BSA Free | NB100-56726SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-24917SS | |||
| Azide and BSA Free | NBP2-77073 | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alexa Fluor 405 | NLS1878AF405 | |||
| Alexa Fluor 488 | NLS1878AF488 | |||
| Alexa Fluor 647 | NLS1878AF647 | |||
| Alexa Fluor 700 | NLS1878AF700 | |||
| Biotin | NLS1878B | |||
| DyLight 405 | NLS1878V | |||
| DyLight 488 | NLS1878G | |||
| DyLight 550 | NLS1878R | |||
| DyLight 650 | NLS1878C | |||
| FITC | NLS1878F | |||
| HRP | NLS1878H | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-77080SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-540SS | |||
| Azide and BSA Free | NBP2-80677 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB110-40766SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB600-1071SS | |||
| Azide and BSA Free | NBP2-80642 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-22115SS | |||
| Azide and BSA Free | NBP2-80618 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-179SS | |||
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP2-12446] - Western blot analysis of TXNIP & NLRP3 protein expression in cultured HK-2 cells treated by normal glucose (5.5 mM), high glucose (30 mM), & NG + mannitol, respectively, for 72 hours, then following 4 hours of hypoxia & 2 hours of reoxygenation in HK-2 cells under high glucose stimulation with or without TXNIP siRNA & RES treatment, respectively. Representative blots (a) & quantitative analysis of Western blots for TXNIP (c) & NLRP3 (d), activity of caspase-1 (e), level of IL-1 beta (f), & Western blot of TXNIP gene knockdown in HK-2 cells (b). The data in (c–f) are means ± SE (n = 5). #P 0.05; *p 0.05; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35463001), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-12446_rabbit-polyclonal-nlrp3-nalp3-antibody-310202416113536.jpg)
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP2-12446] - Exercise training prevents HFD-induced upregulation of cardiac pyroptosis. Western blotting was performed to determine the components of inflammasome complex & pyroptosis in the left ventricle of mice hearts. (A) HFD-fed obese mice show upregulation of the NLRP3 inflammasome in the left ventricle, which is prevented by exercise training. (B) Apoptosis-associated speck adaptor protein (ASC) that assembles with NLRP3 & caspase-1 to make inflammasome complex is elevated in the heart of obese mice but attenuated by exercise training. (C) Exercise training prevents HFD-induced upregulation of cardiac caspase-1. (D) Expression of IL-1 beta , which is upregulated by HFD, is normalized by exercise training. All values are expressed as mean ± SEM with dots of different shape representing each animal in a group. One-way ANOVA & Tukey’s post-hoc test were used for statistical analysis. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31835893), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-12446_rabbit-polyclonal-nlrp3-nalp3-antibody-31020241612224.jpg)
![Immunocytochemistry/ Immunofluorescence: NLRP3/NALP3 Antibody - BSA Free [NBP2-12446] - NLRP3 knockdown decreases corneal inflammation & suppressed neutrophil infiltration in mouse C. albicans keratitis. The C57BL/6 mice were subconjunctivally injected with 6 μL (4 × 108 PFU) of the Ad-GFP-shRNA or Ad-NLRP3-shRNA suspension 3 days before inoculation with 1 × 106 CFU C. albicans or with 5μL sterile PBS after the corneas were scratched. The mouse corneas or eyeballs were collected at 3 dpi & subjected for further detection. RT-qPCR analysis (A), western blot (B) & immunofluorescence staining (C) were used to verify the gene knockdown efficiency of Ad-NLRP3-shRNA (n = 3). Scale bar = 20 μm; magnification 400×. (D) Micrographs of Ad-GFP-shRNA & Ad-NLRP3-shRNA-pretreated mouse corneas were photographed at 3dpi. (E) Clinical score of the infected corneas pretreated with Ad-GFP-shRNA & Ad-NLRP3-shRNA (n = 10). (F) Immunofluorescence staining was performed to assess the levels of neutrophils recruitment in mouse corneas after Ad-GFP-shRNA & Ad-NLRP3-shRNA pretreatment (n =3). Scale bar = 50 μm; magnification 200×. FK: fungal keratitis. All values are presented as mean ± SEM. **p < 0.01; ***p < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35463001), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-12446_rabbit-polyclonal-nlrp3-nalp3-antibody-31020241613619.jpg)
![Immunocytochemistry/ Immunofluorescence: NLRP3/NALP3 Antibody - BSA Free [NBP2-12446] - NLRP3 knockdown decreases corneal inflammation & suppressed neutrophil infiltration in mouse C. albicans keratitis. The C57BL/6 mice were subconjunctivally injected with 6 μL (4 × 108 PFU) of the Ad-GFP-shRNA or Ad-NLRP3-shRNA suspension 3 days before inoculation with 1 × 106 CFU C. albicans or with 5μL sterile PBS after the corneas were scratched. The mouse corneas or eyeballs were collected at 3 dpi & subjected for further detection. RT-qPCR analysis (A), western blot (B) & immunofluorescence staining (C) were used to verify the gene knockdown efficiency of Ad-NLRP3-shRNA (n = 3). Scale bar = 20 μm; magnification 400×. (D) Micrographs of Ad-GFP-shRNA & Ad-NLRP3-shRNA-pretreated mouse corneas were photographed at 3dpi. (E) Clinical score of the infected corneas pretreated with Ad-GFP-shRNA & Ad-NLRP3-shRNA (n = 10). (F) Immunofluorescence staining was performed to assess the levels of neutrophils recruitment in mouse corneas after Ad-GFP-shRNA & Ad-NLRP3-shRNA pretreatment (n =3). Scale bar = 50 μm; magnification 200×. FK: fungal keratitis. All values are presented as mean ± SEM. **p < 0.01; ***p < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35463001), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-12446_rabbit-polyclonal-nlrp3-nalp3-antibody-310202416113526.jpg)
![Immunocytochemistry/ Immunofluorescence: NLRP3/NALP3 Antibody - BSA Free [NBP2-12446] - Heat-killed C. albicans (HKCA) activates NLRP3 inflammasome & induces pyroptosis in human corneal epithelial cells (HCECs). (A) The mRNA expression of NLRP3 in HCECs challenged with HKCA at an MOI of 1:500, 1:50, 1:5, 2:1, or 20:1 respectively for 4 hours was evaluated by RT-qPCR (n = 5). (B–D) The mRNA & protein expression of NLRP3 in HCECs exposed to HKCA (MOI = 20) for 0 (control), 2, 4, 8, 12, or 24 h (n = 3). (E) NLRP3 fluorescence intensity was evaluated using immunofluorescent staining for different times (12–36 h). (n = 3; Scale bar = 20 μm; magnification 400×). (F) Lactate dehydrogenase (LDH) of HCECs treated with HKCA (MOI = 20) for 24 h (n = 6). (G) The mRNA levels of ASC, CASP1, IL-1 beta , IL-18 & GSDMD in HCECs exposed to HKCA (MOI = 20) for different times (n = 3). (H,I) The protein expression of pyroptosis-related proteins (ASC, cleaved CASP1, N-GSDMD, cleaved IL-1 beta & cleaved IL-18) was examined by western blot (n = 3). CASP1: caspase-1; Clv-CASP1: cleaved CASP1; Clv-IL-1 beta : cleaved IL-1 beta ; Clv-IL-18: cleaved IL-18; N-GSDMD: cleaved p30 form of GSDMD. All values are presented as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 vs. control group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35463001), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-12446_rabbit-polyclonal-nlrp3-nalp3-antibody-31020241611470.jpg)
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP2-12446] - The P2X7R inhibitor suppressed PA-induced inflammation, fibrosis & apoptosis in cardiomyocytes. (A) Cell viability was assessed by the CCK8 assay. H9c2 myocytes were incubated in a medium with A438079 at 0–80 μM for 12 h, & cells without A438079 treatment served as the control. (B) H9c2 myocytes were incubated in a medium with PA at 0–800 μM for 24 h, & cells without PA treatment served as the control. (C) Concentrations of IL-1 beta in cell culture supernatants were detected by ELISA. (D) Representative Western blot analysis of P2X7R, NLRP3 inflammasome, collagen I, MMP9, TGF-beta , caspase-1, caspase-3, Bax, & Bcl-2. (E) The protein semiquantification is shown for P2X7R, NLRP3 & caspase-1. (F) The protein semiquantification is shown for collagen I, MMP9 & TGF-beta . (G) The protein semiquantification is shown for caspase-3, Bax, & Bcl-2. (H) The percentages of TUNEL-positive cells are shown. (I) Representative images of TUNEL stained H9c2 myocytes. CON, H9c2 myocytes without any treatment; PA, H9c2 myocytes treated with 200 μM PA for 24 h; PA + A438079, H9c2 myocytes pretreated with A438079 for 12 h, & then treated with 200 μM PA for 24 h. ∗p < 0.05 versus the CON group, #p < 0.05 versus the HFD group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31681001), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-12446_rabbit-polyclonal-nlrp3-nalp3-antibody-31020241613631.jpg)
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP2-12446] - STZ-induced diabetes induces TXNIP expression & NLRP3 inflammasome activation following I/R 48. TXNIP expression was examined by IHC (a), representative blots (b), & quantitative analysis of Western blots for TXNIP (c), NLRP3 (d) & pro-caspase-1 & cleaved caspase-1 (e-f), & release of IL-1 beta & IL-18 by ELISA (g-h). The data in (c–h) are means ± SE (n = 5). ★P < 0.05 versus NS group; #P < 0.05 versus DS group; ▲P < 0.05 versus NI/R group; &P < 0.05 versus DI/R group. NS & DS: nondiabetic & STZ-induced diabetic rats were subjected to sham operation. NI/R & DI/R: nondiabetic & STZ-induced diabetic rats were subjected to 25 min ischemia followed by 48 h reperfusion. DI/R-RES: STZ-induced diabetic rats that underwent I/R were treated with RES (10 mg/kg, ip daily) for 7 consecutive days before renal ischemia-reperfusion. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27867451), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-12446_rabbit-polyclonal-nlrp3-nalp3-antibody-310202416113521.jpg)
![Immunocytochemistry/Immunofluorescence: CD11b Antibody - BSA Free [NB110-89474] - Raw264.7 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with CD11b Antibody (NB110-89474) at 1ug/ml overnight at 4C and detected with an anti-rabbit DyLight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/CD11b-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NB110-89474-img0031.jpg "Immunocytochemistry/Immunofluorescence: CD11b Antibody - BSA Free [NB110-89474] - Raw264.7 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with CD11b Antibody (NB110-89474) at 1ug/ml overnight at 4C and detected with an anti-rabbit DyLight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.")
![Immunocytochemistry/Immunofluorescence: CD11b Antibody - BSA Free [NB110-89474] - Raw264.7 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with CD11b Antibody conjugated to Alexa Fluor 488 (NB110-89474AF488) at 5 ug/ml for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/CD11b-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NB110-89474-img0028.jpg)
![Western Blot: CD11b Antibody - BSA Free [NB110-89474] - Western Blot detection of CD11b in RAW 264.7 whole cell lysates using [NB110-89474].](http://images.novusbio.com/fullsize/CD11b-Antibody---BSA-Free-Western-Blot-NB110-89474-img0013.jpg)
![Immunocytochemistry/Immunofluorescence: CD11b Antibody - BSA Free [NB110-89474] - Staining of mouse pancreas using [NB110-89474] at 1:400 dilution. Nuclei counterstained with 4',6-diamidino-2-phenylindole (DAPI) (blue). ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CD11b-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NB110-89474-img0010.jpg)
![Immunohistochemistry: CD11b Antibody - BSA Free [NB110-89474] - Glibenclamide and Abcc8-/- suppress immune cell infiltration in EAE. White matter of lumbar spinal cord sections from WT control (a), untreated pid-30 WT/EAE (b), glibenclamide-treated pid-30 WT/EAE (c), and pid-30 Abcc8-/-/EAE (d) mice, stained with H&E or immunolabeled for CD45 (leucocyte), CD3 (T cells), CD20 (B cells), or CD11b (macrophage/microglia), as indicated; original magnification, x200 (H&E) or x400 (all immunolabelings). eleft panel: percent of quadrants with inflammatory cells on H&E; four mice/group. efour right panels: Quantification of CD-45-, CD3-, CD20-, and CD11b-expressing cells in white matter; four mice/group; ##P < 0.01 with respect to WT control; **P < 0.01, and ***P < 0.001 with respect to WT/EAE; scale bars, 100 um Image collected and cropped by CiteAb from the following publication (//www.jneuroinflammation.com/content/12/1/210) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD11b-Antibody---BSA-Free-Immunohistochemistry-NB110-89474-img0024.jpg)
![Flow (Cell Surface): CD11b Antibody - BSA Free [NB110-89474] - Surface staining of CD11b in CT26 colorectal carcinoma tumor model. Using Alexa Fluor 405 conjugated version of the antibody (NB110-89474AF405). Image from verified customer review.](http://images.novusbio.com/fullsize/CD11b-Antibody-BSA-Free-Flow-Cell-Surface-NB110-89474-img0033.jpg)
![Immunocytochemistry/Immunofluorescence: CD11b Antibody - BSA Free [NB110-89474] - Raw264.7 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with CD11b Antibody conjugated to Alexa Fluor 647 (NB110-89474AF647) at 5 ug/ml for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/CD11b-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NB110-89474-img0029.jpg)
![Immunocytochemistry/Immunofluorescence: CD11b Antibody - BSA Free [NB110-89474] - Raw264.7 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with CD11b Antibody conjugated to DyLight 650 (NB110-8947C) at 5 ug/ml for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/CD11b-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NB110-89474-img0030.jpg)
![Immunocytochemistry/Immunofluorescence: CD11b Antibody - BSA Free [NB110-89474] - CD11b Antibody [NB110-89474] - CD11b antibody [NB110-89474] was tested in Raw264.7 cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with 4',6-diamidino-2-phenylindole (DAPI) (blue) and DyLight 550 (red).](http://images.novusbio.com/fullsize/CD11b-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NB110-89474-img0009.jpg)
![Immunohistochemistry: CD11b Antibody - BSA Free [NB110-89474] - Population of CD11b + myeloid progenitor cells differentiate into SMA + stromal cells within tumors and in vitro. Representative image of CD11b + SMA + double positive cells within tumor stroma. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32731354/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD11b Antibody - BSA Free-Immunohistochemistry-NB110-89474-img0034.jpg)
![Immunohistochemistry: CD11b Antibody - BSA Free [NB110-89474] - Immunohistochemical analysis of CD11b in human renal cancer with [NB110-89474] using 3,3'-Diaminobenzidine (DAB) with hematoxylin counterstain.](http://images.novusbio.com/fullsize/CD11b-Antibody---BSA-Free-Immunohistochemistry-NB110-89474-img0011.jpg)
![Immunohistochemistry-Frozen: CD11b Antibody - BSA Free [NB110-89474] - Immunohistochemical analysis of frozen sections of mouse spleen using [NB110-89474]. IHC-Fr image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CD11b-Antibody---BSA-Free-Immunohistochemistry-Frozen-NB110-89474-img0021.jpg)
![Immunohistochemistry: CD11b Antibody - BSA Free [NB110-89474] - Representative photomicrographs of cross sections of uteri collected from wild type (WT) mice 24 h after intrauterine infusion with 100 ul of vehicle or 100 ug ultrapure LPS from E. coli O111:B4, and Tlr4-/- mice similarly infused intrauterine with vehicle or LPS. Cross sections were stained with haematoxylin and eosin, and immunostained using a CD11b antibody for granulocytes (red) and DAPI for cell nuclei (white), and images collected at 10X magnification sections (C, F, I, L; bars = 200 um). At least 4 sections per animal and at least 4 fields per section were examined. Only WT mice infused with LPS show evidence of inflammation and accumulation of granulocytes in the endometrium. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0012906) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD11b-Antibody---BSA-Free-Immunohistochemistry-NB110-89474-img0023.jpg)
![Flow (Cell Surface): CD11b Antibody - BSA Free [NB110-89474] - CD11b Antibody [NB110-89474] - A surface stain was performed on Raw264.7 cells with DyLight 550-conjugated [NB110-89474R] (blue) and a matched isotype control (orange). Cells were incubated in an antibody dilution of 10 ug/mL for 20 minutes at room temperature. Both antibodies were conjugated to DyLight 550.](http://images.novusbio.com/fullsize/CD11b-Antibody-BSA-Free-Flow-Cell-Surface-NB110-89474-img0022.jpg)
![Flow (Cell Surface): CD11b Antibody - BSA Free [NB110-89474] - An intracellular stain was performed on THP-1 cells with CD11b NB110-89474 (blue) and a matched isotype control NBP2-24891 (orange). Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).](http://images.novusbio.com/fullsize/CD11b-Antibody-BSA-Free-Flow-Cell-Surface-NB110-89474-img0032.jpg)
![Simple Western: CD11b Antibody - BSA Free [NB110-89474] - Specific band for Cd11b in 1.0 mg/mL of Dentate Gyrus from Rat Brain. [NB110-89474] was used at a dilution of 1:50. This experiment was performed under reducing conditions using the 12-230 kDa separation system. Simple Western image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CD11b-Antibody---BSA-Free-Simple-Western-NB110-89474-img0012.jpg)
![Dual RNAscope ISH-IHC: CD11b Antibody - BSA Free [NB110-89474] - Formalin-fixed paraffin-embedded tissue sections of human lymph node were probed for CD11b mRNA (ACD RNAScope Probe, catalog #555098; Fast Red chromogen, ACD catalog # 322750). Adjacent tissue section was processed for immunohistochemistry using Rabbit Polyclonal (Novus Biologicals catalog #NB110-89474) at 1:50 dilution with 1 hour incubation at room temperature followed by incubation with anti-rabbit IgG VisUCyte HRP Polymer Antibody (Catalog # VC003) and DAB chromogen (yellow-brown). Tissue was counterstained with hematoxylin (blue). Specific staining was localized to lymphocytes.](http://images.novusbio.com/fullsize/CD11b-Antibody---BSA-Free-Dual-RNAscope-ISH-IHC-NB110-89474-img0025.jpg)
![Dual RNAscope ISH-IHC: CD11b Antibody - BSA Free [NB110-89474] - CD14 mRNA (red) and CD11b protein (green) were detected in formalin-fixed paraffin-embedded tissue sections of human malignant lymph node. ACD's Integrated Co-Detection Workflow was performed using ACD RNAScope Probe Hs-CD14 and CD11b antibody at 1:200 dilution. Tissue was stained on Leica Bond RX using RNAscope (TM) 2.5 LS Reagent Kit-RED, BOND Polymer Refine Detection (DAB) and Hematoxylin, BOND Polymer Refine Red Detection and Hematoxylin and RNA scope (TM) 2.5 LS Green Accessory Pack. Tissue was counterstained with 50% hematoxylin (blue).](http://images.novusbio.com/fullsize/CD11b-Antibody---BSA-Free-Dual-RNAscope-ISH-IHC-NB110-89474-img0026.jpg)
![Western Blot: CD11b Antibody - BSA Free [NB110-89474] - Immunodensities of (a) CD11b, (b) GFAP & (c) NF-kappa B (p65) proteins with representative immunoblots in striatum from Munc18-OE (n = 5) & wild-type (n = 5) mice. Bar graphs are ratios of optical densities of our proteins of interest to beta -actin (42 kDa band), expressed as immunoreactivity in percentage of mean value of the WT group (100%). No differences were detected between groups for any of the analyzed proteins. Right panels are representative immunoblots for target proteins & beta -actin which included Munc18-OE (OE) & wild-type (WT) mice samples. The molecular masses were estimated from referenced standards. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25069615), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-89474_rabbit-polyclonal-cd11b-antibody-31020241535670.jpg)
![Immunohistochemistry: CD11b Antibody - BSA Free [NB110-89474] - Comparison of Ki-67 or CD11b immunoreactivity of Aldara-treated dorsal skin samples of C57BL/6 mice using OP or MP. Nuclear proliferation marker Ki-67 immunostaining on OP (a) & MP (b) dorsal skin tissue samples at 400x magnification. Dermal dendritic cells were labelled with anti-CD11b antibody on OP (c) & MP samples (d) at 400x magnification. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30842501), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-89474_rabbit-polyclonal-cd11b-antibody-310202415384158.jpg)
![Immunohistochemistry: CD11b Antibody - BSA Free [NB110-89474] - Comparison of Ki-67 or CD11b immunoreactivity of Aldara-treated dorsal skin samples of C57BL/6 mice using OP or MP. Nuclear proliferation marker Ki-67 immunostaining on OP (a) & MP (b) dorsal skin tissue samples at 400x magnification. Dermal dendritic cells were labelled with anti-CD11b antibody on OP (c) & MP samples (d) at 400x magnification. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30842501), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-89474_rabbit-polyclonal-cd11b-antibody-31020241539450.jpg)
![Western Blot: CD11b Antibody - BSA Free [NB110-89474] - Immunodensities of (a) CD11b, (b) GFAP & (c) NF-kappa B (p65) proteins with representative immunoblots in cerebral cortex from Munc18-OE (n = 5) & wild-type (n = 5) mice. Bar graphs are ratios of optical densities of our proteins of interest to beta -actin (42 kDa band), expressed as immunoreactivity in percentage of the mean value of the WT group (100%). CD11b was significantly decreased in Munc18-OE mice compared to the WT (t = 3.01; P <0.05). No differences between groups were observed in the levels of GFAP or NF-kappa B. Right panels are representative immunoblots for target proteins & beta -actin which included Munc18-OE (OE) & wild-type (WT) mice samples. The molecular masses were estimated from referenced standards. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25069615), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-89474_rabbit-polyclonal-cd11b-antibody-310202415394511.jpg)
![Immunocytochemistry/ Immunofluorescence: CD11b Antibody - BSA Free [NB110-89474] - CD11b staining in IMhu. Cells were stained with antibodies against the CD11b surface antigen. (A) Panel A shows positive staining for CD11b & (B) panel B shows nuclear DAPI staining. Magnitude 40×. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31096716), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-89474_rabbit-polyclonal-cd11b-antibody-310202415291998.jpg)
![Flow Cytometry: TLR2 Antibody (TL2.1) [NB100-56722] - Analysis using the FITC conjugate of NB100-56726. Surface staining of stable HEK293/hTLR2 cells (IML-202, red) and vector control cells (IML-200, green) using TLR2 antibody at 1 ug/10^6 cells.](http://images.novusbio.com/fullsize/TLR2-Antibody-TL2-1-Flow-Cytometry-NB100-56722-img0005.jpg "Flow Cytometry: TLR2 Antibody (TL2.1) [NB100-56722] - Analysis using the FITC conjugate of NB100-56726. Surface staining of stable HEK293/hTLR2 cells (IML-202, red) and vector control cells (IML-200, green) using TLR2 antibody at 1 ug/10^6 cells.")
![Western Blot: TLR2 Antibody (TL2.1) [NB100-56722] - Expression of TLR2 was determined by western blotting. The immunoreactivity of the anti-TLR2 was confirmed with human intestinal lysate. Data are representative for analysis of >=2 independent experiments. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0060671) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR2-Antibody-TL2-1-Western-Blot-NB100-56722-img0015.jpg)
![Western Blot: TLR2 Antibody (TL2.1) [NB100-56722] - Total protein from human THP-1 and U937 cells was separated on a 7.5% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-TLR2 (NB100-56722) in 5% BSA-TBST and detected with an anti-mouse HRP secondary antibody using NovaLume chemiluminescence detection reagent (NPB2-61915).](http://images.novusbio.com/fullsize/TLR2-Antibody-TL2-1-Western-Blot-NB100-56722-img0016.jpg)
![Flow Cytometry: TLR2 Antibody (TL2.1) [NB100-56722] - Monitoring of TLR2 expression in normal B cells and primary MCL cells cultured for 24h in the absence/presence of CD40L, IL-4, and TLR ligands. Filled curves refer to isotypic control, empty curves to the TLR2 antibody (NB100-56722) of untreated samples. Dotted histograms represent CD40L+IL4 activated cells, dashed curves indicate CD40L+IL4 activated cells further treated with TLR ligands. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0153823) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR2-Antibody-TL2-1-Flow-Cytometry-NB100-56722-img0013.jpg)
![Flow (Cell Surface): TLR2 Antibody (TL2.1) [NB100-56722] - Flow (Cell Surface): - Azide Free [NB100-56726] - Analysis using the PE conjugate of NB100-56726. Staining of TLR2 on stable transfected cell line using this antibody at 1 ug/10^6 cells. Green: isotype control. Red: anti-TLR2 antibody. Image using the Azide Free form of this antibody.](http://images.novusbio.com/fullsize/TLR2-Antibody-TL2-1-Flow-Cell-Surface-NB100-56722-img0010.jpg)
![Block/Neutralize: TLR2 Antibody (TL2.1) [NB100-56722] - Human monocyte-derived DCs were pre-incubated wit TLR-neutralizing antibodies including TLR2 antibody (NB100-56722) for 1 h. Afterwards, DCs were infected with H. pylori G27 (MOI 5) and the levels of the costimulatory molecule CD86 and the maturation marker CD83 were analyzed by FACS on CD11c+ cells 24 h post-infection. Data are presented as mean +/- SD of five independent experiments. *p<=0.05, **p<=0.005, ***p<=0.0005. Asterisks on top of bars indicate significance relative to non-neutralized, H. pylori-primed control cells. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0104804) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR2-Antibody-TL2-1-Block-Neutralize-NB100-56722-img0014.jpg)
![Flow Cytometry: TLR2 Antibody (TL2.1) - BSA Free [NB100-56722] - Intracellular flow analysis of TLR2 in 1x10^6 PBMCs using 2 ug of NB100-56722. Shaded histogram represents cells without antibody; green represents isotype control; purple represents anti-TLR2 antibody.](http://images.novusbio.com/fullsize/nb100-56722_mouse-monoclonal-tlr2-antibody-tl2-1-17720241003212.jpg)
![Flow Cytometry: TLR8 Antibody (44C143) [NBP2-24917] - Intracellular expression of TLR8 in monocyte-derived macrophages (MDMs). MDMs which were incubated with PE-conjugated anti-TLR8 or isotype antibody control. Intracellular expression was determined by flow cytometry. Representative profiles were similar in four independent experiments (n=4 subjects). Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0104039) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR8-Antibody-44C143-Flow-Cytometry-NBP2-24917-img0018.jpg "Flow Cytometry: TLR8 Antibody (44C143) [NBP2-24917] - Intracellular expression of TLR8 in monocyte-derived macrophages (MDMs). MDMs which were incubated with PE-conjugated anti-TLR8 or isotype antibody control. Intracellular expression was determined by flow cytometry. Representative profiles were similar in four independent experiments (n=4 subjects). Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0104039) licensed under a CC-BY license.")
![Flow Cytometry: TLR8 Antibody (44C143) [NBP2-24917] - Expression of TLR8 in Fravel, L363, OPM1, RPMI8226, XG1, and NCI-H929 as determined by flow cytometry. HCMLs were stained using an intracellular staining protocol with TLR8 antibodies followed by relevant secondary fluorescent-conjugated antibodies. Filled histograms (purple) represent the isotype controls and the open histograms (red) indicate TLR8. Data are representative for analysis of >=2 independent experiments. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0060671) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR8-Antibody-44C143-Flow-Cytometry-NBP2-24917-img0021.jpg)
![<b>Orthogonal Strategies Validation. </b>Western Blot: TLR8 Antibody (44C143) [NBP2-24917] - All the cell lines expressed mRNA for TLR8 (Figure 1) and displayed a strong expression of TLR8 protein (Figure 2). Lysates of human intestinal tissue and mouse splenocytes were used as positive controls. Beta-actin was served as loading control and was used to normalize expression levels between cells. Data are representative for analysis of >=2 independent experiments. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0060671) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR8-Antibody-44C143-Western-Blot-NBP2-24917-img0022.jpg)
![Immunohistochemistry-Paraffin: TLR8 Antibody (44C143) [NBP2-24917] - Formalin-fixed, paraffin-embedded human spleen stained with TLR8 antibody at 2 ug/ml.](http://images.novusbio.com/fullsize/TLR8-Antibody-44C143-Immunohistochemistry-Paraffin-NBP2-24917-img0005.jpg)
![Flow Cytometry: TLR8 Antibody (44C143) [NBP2-24917] - HEK cells expressing TLR8 were treated with ssRNA40-Alexa 546 followed by fixation, permeablization and staining for TLR8 using anti-TLR8 Alexa 488 conjugate or isotype control IgG1/Kappa Alexa 488. TLR8 detection is shown along the horizontal axis, and ssRNA40 Alexa 546 detection is shown along the vertical axis. Direct excitation (488 and 561 nm lasers) of both fluorophores (Alexa 488 and Alexa 546) allowed quantitation of cells staining positive for TLR8 (anti-TLR8-Alexa488) and cells that had taken up ssRNA40-Alexa 546. Single-stranded RNA40 binds TLR8 (flow cytometry FRET assay). A representative experiment is shown from three independent experiments with similar results. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0104039) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR8-Antibody-44C143-Flow-Cytometry-NBP2-24917-img0019.jpg)
![Western Blot: TLR8 Antibody (44C143) [NBP2-24917] - Analysis of TLR8 in human Ramos cell lysate. Goat anti-mouse Ig HRP secondary antibody and PicoTect ECL substrate solution were used for this test.](http://images.novusbio.com/fullsize/TLR8-Antibody-44C143-Western-Blot-NBP2-24917-img0006.jpg)
![Simple Western: TLR8 Antibody (44C143) [NBP2-24917] - Simple Western lane view shows a specific band for TLR8 in 0.5 mg/ml of Ramos (left) and Human Spleen (right) lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system. * Non-specific interaction with the 230 kDa Simple Western standard may be seen with this antibody Image from the standard format of this antibody.](http://images.novusbio.com/fullsize/TLR8-Antibody-44C143-Simple-Western-NBP2-24917-img0023.jpg)
![Western Blot: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Immunoblot of FPR2 protein in various parts of the rat brain including olfactory bulb (OB), prefrontal cortex (PFC), primary somatosensory cortex (CTX1), parietal association cortex and secondary auditory cortex (CTX2), striatum (STR), thalamus and hypothalamus (THA), hippocampus (HPC), cerebellum (CB), brainstem (BS), cervical spinal cord [SC(C)], thoracic spinal cord [SC(T)], and lumbar spinal cord [SC(L)]. Blots incubated with antigen-absorbed antibody i. e. peptide competition, show reduced band intensities. Image collected and cropped by Citeab from the following publication (Localisation of Formyl-Peptide Receptor 2 in the Rat Central Nervous System and Its Role in Axonal and Dendritic Outgrowth. Neurochem Res (2018)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Western-Blot-NLS1878-img0012.jpg "Western Blot: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Immunoblot of FPR2 protein in various parts of the rat brain including olfactory bulb (OB), prefrontal cortex (PFC), primary somatosensory cortex (CTX1), parietal association cortex and secondary auditory cortex (CTX2), striatum (STR), thalamus and hypothalamus (THA), hippocampus (HPC), cerebellum (CB), brainstem (BS), cervical spinal cord [SC(C)], thoracic spinal cord [SC(T)], and lumbar spinal cord [SC(L)]. Blots incubated with antigen-absorbed antibody i. e. peptide competition, show reduced band intensities. Image collected and cropped by Citeab from the following publication (Localisation of Formyl-Peptide Receptor 2 in the Rat Central Nervous System and Its Role in Axonal and Dendritic Outgrowth. Neurochem Res (2018)) licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Mouse J774A.1, mouse reticulum cell sarcoma macrophage cell line. Left panel is + Anti-Rabbit FITC; middle panel indicates the cell nuclei stained with Hoechst; the right panel is a merged image. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NLS1878-img0008.jpg)
![Immunohistochemistry-Paraffin: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - SPM receptors differentially expressed on endothelium and infiltrating leukocytes AE](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Immunohistochemistry-Paraffin-NLS1878-img0011.jpg)
![Flow Cytometry: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Flow Cytometry: [Alexa Fluor® 700] [NLS1878AF700] - Mouse splenocytes. Cells were pre-gated with live/dead and FSC-A/W to exclude dead cells and cell doublets. Image from verified customer review. Image using the Alexa Fluor 700 form of this antibody.](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Flow-Cytometry-NLS1878-img0007.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Murine neutrophils were extracted from the bone marrow of C57BL/6 mice and exposed to normal glucose (90 mg/dl) or high glucose (300 mg/dl) and the expression of FPR2 was assessed by western blotting after 1, 2, or 3 hr exposure to glucose. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35112667/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FPRL1-FPR2 Antibody - BSA Free-Western Blot-NLS1878-img0013.jpg)
![Western Blot: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Analysis in HL-60 cell lysate.](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Western-Blot-NLS1878-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Antibody was tested in Raw264.7 cells with DyLight 488 (green). Nuclei were counterstained with DAPI (blue).](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NLS1878-img0005.jpg)
![Immunohistochemistry: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Analysis in human kidney cancer using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Immunohistochemistry-NLS1878-img0006.jpg)
![Electron Microscopy: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Electron micrographs of FPR2 immunostained sections from the prefrontal cortex. Immunostaining is mostly present in axon pre-terminals (PrT) that did not form synapses with postsynaptic structures. Occasional labelled dendrites (DE) are also found, that formed asymmetrical synapses (S) with unlabelled axon terminals (AT). Scale: a, b, c=50A nm, e=100A nm. Image collected and cropped by Citeab from the following publication (Localisation of Formyl-Peptide Receptor 2 in the Rat Central Nervous System and Its Role in Axonal and Dendritic Outgrowth. Neurochem Res (2018)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Electron-Microscopy-NLS1878-img0010.jpg)
![Immunohistochemistry: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Electron micrographs of FPR2 immunostained sections from the prefrontal cortex. a, b Immunostaining is mostly present in axon pre-terminals (PrT) that did not form synapses with postsynaptic structures. c Occasional axon terminals (AT) are observed to form asymmetrical, putatively glutamatergic synapses (S) with unlabelled dendrites (DE). d Occasional labelled dendrites (DE) are also found, that formed asymmetrical synapses (S) with unlabelled axon terminals (AT). Scale: a, b, c = 50 nm, e = 100 nm Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29948727), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nls1878_rabbit-polyclonal-fprl1-fpr2-antibody-310202415382420.jpg)
![Immunohistochemistry: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Electron micrographs of FPR2 immunostained sections from the prefrontal cortex. a, b Immunostaining is mostly present in axon pre-terminals (PrT) that did not form synapses with postsynaptic structures. c Occasional axon terminals (AT) are observed to form asymmetrical, putatively glutamatergic synapses (S) with unlabelled dendrites (DE). d Occasional labelled dendrites (DE) are also found, that formed asymmetrical synapses (S) with unlabelled axon terminals (AT). Scale: a, b, c = 50 nm, e = 100 nm Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29948727), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nls1878_rabbit-polyclonal-fprl1-fpr2-antibody-31020241534335.jpg)
![Immunohistochemistry: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Electron micrographs of FPR2 immunostained sections from the prefrontal cortex. a, b Immunostaining is mostly present in axon pre-terminals (PrT) that did not form synapses with postsynaptic structures. c Occasional axon terminals (AT) are observed to form asymmetrical, putatively glutamatergic synapses (S) with unlabelled dendrites (DE). d Occasional labelled dendrites (DE) are also found, that formed asymmetrical synapses (S) with unlabelled axon terminals (AT). Scale: a, b, c = 50 nm, e = 100 nm Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29948727), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nls1878_rabbit-polyclonal-fprl1-fpr2-antibody-31020241534380.jpg)
![Immunohistochemistry: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Electron micrographs of FPR2 immunostained sections from the prefrontal cortex. a, b Immunostaining is mostly present in axon pre-terminals (PrT) that did not form synapses with postsynaptic structures. c Occasional axon terminals (AT) are observed to form asymmetrical, putatively glutamatergic synapses (S) with unlabelled dendrites (DE). d Occasional labelled dendrites (DE) are also found, that formed asymmetrical synapses (S) with unlabelled axon terminals (AT). Scale: a, b, c = 50 nm, e = 100 nm Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29948727), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nls1878_rabbit-polyclonal-fprl1-fpr2-antibody-310202415382435.jpg)
![Immunocytochemistry/ Immunofluorescence: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Lipoxin A4, along with its precursors & ligand, were altered by hAECs. (A): Expression of the lipoxin A4 precursor genes ALOX‐5, ‐12, & ‐15 was increased at days 5 & 7 compared with saline controls (ALOX‐5: 0.393 ± 0.114 vs. 3.777 ± 1.98; ALOX‐12: 0.484 ± 0.248 vs. 1.520 ± 0.203; ALOX‐15: 0.020 ± 0.007 vs. 1.998 ± 0.983). ∗, p < .05. (B): Lipoxin A4 protein levels were elevated in lung lysates at day 7 in animals treated with hAECs compared with controls (0.103 ± 0.021 ng/ml vs. 0.249 ± 0.072 ng/ml, respectively). ∗, p < .05. (C): At day 7, bleomycin challenge resulted in positively stained F4/80/FPR2 cells, which were was elevated in mice treated with hAECs compared with control mice (5.720% ± 0.587% vs. 8.795% ± 0.687%, respectively). ∗, p < .05. (D): Representative images of F4/80‐ & FPR2‐positive‐stained lung sections from hAEC‐treated animals. Magnification: ×200. Scale bar =100 μm. Abbreviations: DAPI, 4′,6‐diamidino‐2‐phenylindole; FPR2, N‐formyl peptide receptor 2; hAEC, human amnion epithelial cell. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28371562), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nls1878_rabbit-polyclonal-fprl1-fpr2-antibody-310202416114742.jpg)
![Western Blot: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Higher expression of Fpr2 in the livers of female mice is related with hepatocyte protection.a qRT-PCP analysis for Fpr2 expression in primary hepatocytes (pHEPs) from WT (male n = 2, female n = 2) & KO mice (male n = 2, female n = 2). Total eight mice were employed in each hepatocyte isolation, & the experiments were replicated at least three times & the mean ± S.E.M. results are graphed (*p < 0.05, **p < 0.005 vs WT male-pHEPs). b Western blot analysis & c double immunofluorescent images of Fpr2 (red) with albumin (green) in these cells. Gapdh was used as internal control. DAPI (blue) was used as nuclear counterstaining. Data shown represent one of three experiments with similar results (Scale bar, 20 μm). d qRT-PCR analysis for Fpr2 & glucose-6-phosphatase (G6pc) in, e cell viability of, & f western blot analysis of cleaved Caspase-3 & pro Caspase-3 in WT & KO female mice-isolated pHEPs treated with vehicle (Veh) or 250 μM of palmitate (PA). The data shown represent one of three experiments with similar results. The mean ± S.E.M. results obtained from three repetitive experiments are graphed (*p < 0.05, **p < 0.005 vs WT-Veh). Gray circles represent individual data points. See Supplementary Data for statistical details. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35102146), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nls1878_rabbit-polyclonal-fprl1-fpr2-antibody-3102024161228.jpg)
![Immunohistochemistry-Paraffin: CCR7 Antibody [NB100-712] - M1 and M2 macrophages showed similar expression patterns in cortical bone. IHC staining was performed in sagittal serial sections of medial condyles from 6-week-old rats within the diaphyseal region. Cluster of differentiation 68 (CD68) was selected as a pan marker for the macrophage lineage, including monocytes, macrophages, giant cells, and osteoclasts. iNOS and C-C chemokine receptor type 7 (CCR7) were selected as M1 phenotypic markers, whereas Arginase1 and cluster of differentiation 163 (CD163) were selected as M2 phenotypic markers. Tartrate-resistant acid phosphatase (TRAP) staining was performed as described in Materials and Methods. Quantification of cell numbers according to their location revealed that most of the M1 and M2 cells were not attached to the bone surfaces. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/boneres201719) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CCR7-Antibody-Immunohistochemistry-Paraffin-NB100-712-img0006.jpg "Immunohistochemistry-Paraffin: CCR7 Antibody [NB100-712] - M1 and M2 macrophages showed similar expression patterns in cortical bone. IHC staining was performed in sagittal serial sections of medial condyles from 6-week-old rats within the diaphyseal region. Cluster of differentiation 68 (CD68) was selected as a pan marker for the macrophage lineage, including monocytes, macrophages, giant cells, and osteoclasts. iNOS and C-C chemokine receptor type 7 (CCR7) were selected as M1 phenotypic markers, whereas Arginase1 and cluster of differentiation 163 (CD163) were selected as M2 phenotypic markers. Tartrate-resistant acid phosphatase (TRAP) staining was performed as described in Materials and Methods. Quantification of cell numbers according to their location revealed that most of the M1 and M2 cells were not attached to the bone surfaces. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/boneres201719) licensed under a CC-BY license.")
![Immunohistochemistry-Paraffin: CCR7 Antibody [NB100-712] - Mouse spleen](http://images.novusbio.com/fullsize/CCR7-Antibody-Immunohistochemistry-Paraffin-NB100-712-img0001.jpg)
![Immunohistochemistry-Paraffin: CCR7 Antibody [NB100-712] - Mouse spleen](http://images.novusbio.com/fullsize/CCR7-Antibody-Immunohistochemistry-Paraffin-NB100-712-img0004.jpg)
![Immunohistochemistry-Paraffin: CCR7 Antibody [NB100-712] - Human spleen](http://images.novusbio.com/fullsize/CCR7-Antibody-Immunohistochemistry-Paraffin-NB100-712-img0005.jpg)
![Immunohistochemistry: CCR7 Antibody [NB100-712] - M1 expression pattern changed in trabecular bone. Immunohistochemical staining was performed in sagittal serial sections of medial condyles from 6-week-old rats within the epiphyseal region. The region with the solid line indicates areas of interest to be enlarged in the following image. Representative staining with the anticluster of differentiation 68 (CD68) antibody demonstrated that CD68+ cells were either attached (black arrows) or unattached (white arrows) to the bone surfaces with a variety of sizes & shapes (a, b). TRAP+ cells showed multinucleated morphology (black arrows) which is similar to the CD68+ cells (c, d). Inducible nitric oxide synthase-positive (iNOS+) & C-C chemokine receptor type 7-positive (CCR7+) cells (black arrow) were attached to the bone surfaces with an elongated morphology (e, f, i, j). Arginase1+ & cluster of differentiation 163-positive (CD163+) cells (white arrow) represented the predominant population in the reticular connective tissue with similar expression patterns as in the cortical bone (g, h, k, l). No positive staining was found in isotype controls (data not shown). Most of the M1-labeled cells were found attached to bone surfaces instead of M2-labeled cells (m). Representative images from three independent experiments are shown. FOV, field of view. Data shown as the mean±s.d. (*P<0.05). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29263936), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-712_goat-polyclonal-ccr7-antibody-310202415532041.jpg)
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - HMGB1 promoted the activation of canonical NLRP3 inflammasome in retinal IR injury. The intravitreal injection of HMGB1 inhibitor, GA, significantly suppressed mRNA (B) and protein (D) production of NLRP3. Data are shown as mean +/- SD. **P < 0.01 vs sham group. Image collected and cropped by CiteAb from the following publication (//www.jneuroinflammation.com/content/12/1/137) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/NLRP3-NALP3-Antibody---BSA-Free-Western-Blot-NBP1-77080-img0011.jpg "Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - HMGB1 promoted the activation of canonical NLRP3 inflammasome in retinal IR injury. The intravitreal injection of HMGB1 inhibitor, GA, significantly suppressed mRNA (B) and protein (D) production of NLRP3. Data are shown as mean +/- SD. **P < 0.01 vs sham group. Image collected and cropped by CiteAb from the following publication (//www.jneuroinflammation.com/content/12/1/137) licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - Staining of NALP3 in K562 cells with NALP3 antibody at 2 ug/mL.](http://images.novusbio.com/fullsize/NLRP3-NALP3-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NBP1-77080-img0010.jpg)
![Immunohistochemistry-Paraffin: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - Analysis of NALP3 in mouse lung tissue using anti-NALP3 antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/NLRP3-NALP3-Antibody---BSA-Free-Immunohistochemistry-Paraffin-NBP1-77080-img0003.jpg)
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - Analysis of NALP3 in K562 cell lysate with NALP3 antibody at 1 ug/mL (A) in the absence and (B) in the presence of blocking peptide.](http://images.novusbio.com/fullsize/NLRP3-NALP3-Antibody---BSA-Free-Western-Blot-NBP1-77080-img0009.jpg)
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - hADSC-Evs suppressed NLRP3 inflammasome activation in ocular surface of experimental mice under desiccating stress. Representative image of immunofluorescent staining of NLRP3 related genes in corneal and conjunctival epithelia of desiccating mice or treated with hADSC-EVs (*conjunctiva; open triangle cornea). Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32884023/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/NLRP3-NALP3 Antibody - BSA Free-Immunocytochemistry-Immunofluorescence-NBP1-77080-img0012.jpg)
![Immunocytochemistry/ Immunofluorescence: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - hADSC-Evs suppressed NLRP3 inflammasome activation in ocular surface of experimental mice under desiccating stress. (A) Representative image of immunofluorescent staining of NLRP3 related genes in corneal & conjunctival epithelia of desiccating mice or treated with hADSC-EVs (*conjunctiva; open triangle cornea). (B,C) qRT-PCR showed the mRNA levels of NLRP3 related genes in conjunctiva & cornea (four corneas/conjunctivas were mixed as a sample). Data was shown as mean ± SEM. *p < 0.05. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32884023), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77080_rabbit-polyclonal-nlrp3-nalp3-antibody-31020241535675.jpg)
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - HMGB1 promoted the activation of canonical NLRP3 inflammasome in retinal IR injury. The intravitreal injection of exogenous rHMGB1 significantly promoted the mRNA & protein production of NLRP3 (a, c) & ASC (e, g) & activation of caspase-1 (i). Thus, the intravitreal injection of HMGB1 inhibitor, GA, significantly suppressed the production of NLRP3 (b, d) & ASC (f, h) & activation of caspase-1 (j). Data are shown as mean ± SD. *P < 0.05, **P < 0.01 vs sham group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26224068), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77080_rabbit-polyclonal-nlrp3-nalp3-antibody-310202415345338.jpg)
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - Co-immunoprecipitation assay: Figure showing interaction of NLRP3, NLRC4 & NAIP with ASC during CFT073 infection in THP-1m. Cytoplasmic extracts of THP-1m infected with or without CFT073, 6 h post stimulation were subjected to IP & WB by various antibodies (ASC, NLRP3, NLRC4, & NAIP) as described in material & methods. Cytoplasmic extract used as input was subjected to check NLRP3, ASC, NLRC4 & NAIP expression as shown in figure. ASC antibody was used to co-immunoprecipitate the complex from cytoplasmic extracts & then immunoblotted to detect NLRP3, NLRC4 & NAIP. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31551961), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77080_rabbit-polyclonal-nlrp3-nalp3-antibody-310202415371971.jpg)
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - HMGB1 regulated the activation of NLRP3, rather than the activation of caspase-8, via NF-kappa B pathway. a, b NF-kappa B was activated in ischemic retina at the early stage after reperfusion. c, d Intraocular injection rHMGB1 or GA could promote or suppress the production of phosphor-NF-kappa B p65. e, f Intravitreal injection of NF-kappa B p65 inhibitor, JSH-23, significantly reduced the activation of NLRP3 & decreased the processing of IL-1 beta , g rather than caspase-8. However, intravitreal injection of caspase-8 inhibitor, Z-IETD-fmk, decreased the production of phosphor-NF-kappa B p65, obviously (h). Data are shown as mean ± SD. *P < 0.05, **P < 0.01 vs sham group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26224068), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77080_rabbit-polyclonal-nlrp3-nalp3-antibody-310202415291993.jpg)
![Flow (Intracellular): Complement C3 Antibody (11H9) [NB200-540] - An intracellular stain was performed on RAW 246.7 cells with Complement C3 (11H9-3-2) antibody NB200-540 (blue) and a matched isotype control NBP2-31382 (orange). Cells were either treated with 3uM Monensin for 3 hours to block the secretion of Complement C3 (B) or grown in normal media (A). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2 ug/mL for 30 minutes at room temperature, followed by mouse F(ab)2 IgG (H+L) PE-conjugated secondary antibody (F0102B, R&D Systems).](http://images.novusbio.com/fullsize/Complement-C3-Antibody-11H9-Flow-Intracellular-NB200-540-img0005.jpg "<b>Biological Strategies Validation. </b>Flow (Intracellular): Complement C3 Antibody (11H9) [NB200-540] - An intracellular stain was performed on RAW 246.7 cells with Complement C3 (11H9-3-2) antibody NB200-540 (blue) and a matched isotype control NBP2-31382 (orange). Cells were either treated with 3uM Monensin for 3 hours to block the secretion of Complement C3 (B) or grown in normal media (A). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2 ug/mL for 30 minutes at room temperature, followed by mouse F(ab)2 IgG (H+L) PE-conjugated secondary antibody (F0102B, R&D Systems).")
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: Complement C3 Antibody (11H9) [NB200-540] - C3 protein fragments deposited on kidney cells of MPL-lpr mouse. Staining with antibody 11H9. Glomerular staining pattern. Fixation in 4% paraformaldehyde in PBS pH 7.4. Vibratome sections of 4 um. Pretreated with 3% hydrogen peroxide for 20 min to quench endogenous peroxidases. Microwaved in antigen unmasking solution for 2-5 minutes as antigen retrieval.](http://images.novusbio.com/fullsize/Complement-C3-Antibody-11H9-Immunocytochemistry-Immunofluorescence-NB200-540-img0002.jpg)
![Immunohistochemistry-Paraffin: Complement C3 Antibody (11H9) [NB200-540] - Complement C3 protein in a FFPE tissue section of mouse liver using 1:100 dilution of Complement C3 antibody (clone 11H9) NB200-540. Weak but distinct membrane-cytoplasmic immunopositivity was observed in hepatocytes and few cells developed punctate membrane staining.](http://images.novusbio.com/fullsize/Complement-C3-Antibody-11H9-Immunohistochemistry-Paraffin-NB200-540-img0004.jpg)
![Flow Cytometry: Complement C3 Antibody (11H9) [NB200-540] - Left panel: FMO, Middle panel: No primary antibody control, Right panel: sample. Day 6 murine mammary tumors processed and stained for analysis with flow cytometry. The C3b+ population of CD45+ cells is what the gate in each sample is exhibiting. WB image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Complement-C3-Antibody-11H9-Flow-Cytometry-NB200-540-img0006.jpg)
![Immunohistochemistry-Paraffin: Complement C3 Antibody (11H9) [NB200-540] - Complement C3 protein in a FFPE tissue section of mouse lymph node using 1:100 dilution of Complement C3 antibody (clone 11H9) NB200-540. This representative photomicrograph shows a membrane-cytoplasmic immunopositivity in non-germinal center cells, and few cells developed an intense staining for this target protein.](http://images.novusbio.com/fullsize/Complement-C3-Antibody-11H9-Immunohistochemistry-Paraffin-NB200-540-img0003.jpg)
![Western Blot: CD11b/c Antibody - BSA Free [NB110-40766] - Analysis of CD11b/c in Raw 264.7 whole cell lysate.](http://images.novusbio.com/fullsize/CD11b-c-Antibody---BSA-Free-Western-Blot-NB110-40766-img0002.jpg "Western Blot: CD11b/c Antibody - BSA Free [NB110-40766] - Analysis of CD11b/c in Raw 264.7 whole cell lysate.")
![Immunocytochemistry/Immunofluorescence: CD11b/c Antibody - BSA Free [NB110-40766] - CD11 antibody was tested in Raw264.7 cells with FITC (green). Nuclei were counterstained with DAPI (blue).](http://images.novusbio.com/fullsize/CD11b-c-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NB110-40766-img0006.jpg)
![Immunohistochemistry-Frozen: CD11b/c Antibody - BSA Free [NB110-40766] - 10 um Cryosection of murine acute brain slices stained with CD11b/c antibody (1:300 = 3.3 ug/ml) and Alexa Fluor 555 donkey anti rabbit IgG. Antibody shows specific staining, but the background is quite heavy. Image from verified customer review.](http://images.novusbio.com/fullsize/CD11b-c-Antibody---BSA-Free-Immunohistochemistry-Frozen-NB110-40766-img0009.jpg)
![Flow Cytometry: CD11b/c Antibody - BSA Free [NB110-40766] - A surface stain was performed on RAW 264.7 with NB110-40766 and a matched isotype control. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, DyLight 550.](http://images.novusbio.com/fullsize/CD11b-c-Antibody---BSA-Free-Flow-Cytometry-NB110-40766-img0008.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: CD11b/c Antibody - BSA Free [NB110-40766] - Effects of oltipraz on the expression of CD11b/c, phosphoinositide 3-kinase (PI3K), phosphorylated protein kinase B (p-Akt), and phosphorylated inhibitor of kB alpha (p-IkB alpha) in the spinal cord of the CCI-injured mice. The relative protein levels of (A) CD11b/c and (B) PI3K on the ipsilateral side of the spinal cord in the CCI-injured mice treated with oltipraz (OLT) or vehicle are represented. (C) Representative examples of blots for CD11b/c (160 kDa), PI3K (130 kDa), and GAPDH (37 kDa). Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31234342/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD11b-c Antibody - BSA Free-Western Blot-NB110-40766-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: CD11b/c Antibody - BSA Free [NB110-40766] - Phase contrast microscopy images of HFA and brain tumor cells and immunofluorescence images of cultured primary brain tumor cells, AA and HFA. HFA were derived from three different fetal brains. HFA from an 18-week- old fetus (passaged once) - GFAP (DAKO) merged with DAPI and CD68 (zoomed: 2.1x magnification); GFAP (green and red) was used as an astrocyte marker and CD68 (red) and CD11b (green) were used as markers for microglia. Nuclei indicated by DAPI (blue) in all images. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0112945), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD11b-c-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NB110-40766-img0010.jpg)
![Immunohistochemistry: CD11b/c Antibody - BSA Free [NB110-40766] - Staining of human bone marrow, myeloid precursors.](http://images.novusbio.com/fullsize/CD11b-c-Antibody---BSA-Free-Immunohistochemistry-NB110-40766-img0007.jpg)
![Western Blot: CD11b/c Antibody - BSA Free [NB110-40766] - Effects of oltipraz on the expression of CD11b/c, phosphoinositide 3-kinase (PI3K), phosphorylated protein kinase B (p-Akt), & phosphorylated inhibitor of kappa B alpha (p-IkB alpha ) in the spinal cord of the CCI-injured mice. The relative protein levels of (A) CD11b/c, (B) PI3K, (D) p-Akt, & (E) p-IKB alpha on the ipsilateral side of the spinal cord in the CCI-injured mice treated with oltipraz (OLT) or vehicle are represented. The sham-operated mice (SHAM) treated with vehicle were used as controls. (C) Representative examples of blots for CD11b/c (160 kDa), PI3K (130 kDa), & GAPDH (37 kDa), & (F) for p-Akt (60 kDa), Akt (60 kDa), p-IKB alpha (40 kDa) & IKB alpha (40 kDa). CD11b/c & PI3K are expressed relative to GAPDH levels whereas phosphorylated proteins are expressed relative to their corresponding total proteins. In all panels, * denotes significant differences vs. sham-operated mice treated with vehicle (p < 0.05; one-way ANOVA followed by the SNK test). Results are presented as the mean ± SEM; n = 5 samples per experimental group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31234342), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-40766_rabbit-polyclonal-cd11b-c-antibody-310202416235533.jpg)
![Western Blot: CD11b/c Antibody - BSA Free [NB110-40766] - Effects of oltipraz on the expression of CD11b/c, PI3K, p-Akt, & p-IkB alpha in the prefrontal cortex of the CCI-injured mice. The relative protein levels of (A) CD11b/c, (B) PI3K, (D) p-Akt, & (E) p-IKB alpha in the prefrontal cortex of the CCI-injured mice treated with oltipraz (OLT) or vehicle. The sham-operated mice (SHAM) treated with vehicle were used as controls. Representative examples of blots for (C) CD11b/c (160 kDa), PI3K (130 kDa) & GAPDH (37 kDa), & for (F) p-Akt (60 kDa), Akt (60 kDa), p-IKB alpha (40 kDa) & IKB alpha (40 kDa). CD11b/c & PI3K are expressed relative to GAPDH levels whereas phosphorylated proteins are expressed relative to their corresponding total proteins. In all panels, * denotes significant differences vs. sham-operated mice treated with vehicle (p < 0.05; one-way ANOVA followed by the SNK test). Results are presented as the mean ± SEM; n = 4-–5 samples per experimental group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31234342), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-40766_rabbit-polyclonal-cd11b-c-antibody-310202416235518.jpg)
![Western Blot: CD11b/c Antibody - BSA Free [NB110-40766] - Effects of oltipraz on the expression of CD11b/c, PI3K, p-Akt, & p-IkB alpha in the hippocampus of the CCI-injured mice. The relative protein levels of (A) CD11b/c, (B) PI3K, (D) p-Akt, & (E) p-IKB alpha in the hippocampus of the CCI-injured mice treated with oltipraz (OLT) or vehicle. The sham-operated mice (SHAM) treated with vehicle were used as controls. Representative examples of blots for (C) CD11b/c (160 kDa), PI3K (130 kDa), & GAPDH (37 kDa); & (F) for p-Akt (60 kDa), Akt (60 kDa), p-IKB alpha (40 kDa), & IKB alpha (40 kDa). CD11b/c & PI3K are expressed relative to GAPDH levels whereas phosphorylated proteins are expressed relative to their corresponding total proteins. In all panels, * denotes significant differences vs. sham-operated mice treated with vehicle (p < 0.05; one-way ANOVA followed by the SNK test). Results are presented as the mean ± SEM; n = 5 samples per experimental group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31234342), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-40766_rabbit-polyclonal-cd11b-c-antibody-310202416235538.jpg)
![Immunocytochemistry/ Immunofluorescence: CD11b/c Antibody - BSA Free [NB110-40766] - Phase contrast microscopy images of HFA & brain tumor cells & immunofluorescence images of cultured primary brain tumor cells, AA & HFA.HFA were derived from three different foetal brains. (A) 18-week foetus (10× magnification); (B) 19-week foetus, first week in culture (10× magnification); (C) 19-week foetus, day 5 in culture (20× magnification); (D) Primary GBM after 2 trypsinisations (20x); (E) Recurrent GBM (20x); (F) Secondary GBM after 3 trypsinisations (10x); (G) OII 14 days in culture (10x); (H) AII 13 days in culture (10x); (I) Negative control for NGS merged with DAPI; (J) Negative control for secondary antibodies merged with DAPI; (K) GBM cells derived from one patient – GFAP (DAKO) merged with DAPI & CD68 (zoomed: 2.4× magnification); (L) primary brain tumor cells from one patient (male, 40 years old) (passaged three times) - GFAP (Novocastra) merged with DAPI; (K & L) GFAP (green) was used as a GBM marker & CD68 (red) was used as a marker for microglia. (M) AA from one Female, 61 years old; (passaged twice) - GFAP (Novocastra) merged with DAPI; (N) AA from one male 40 years old; (passaged once) - GFAP (Sigma) merged with DAPI & CD68 (Abcam); (M & N) GFAP (green) was used as an astrocyte marker & CD68 (red) & CD11b (green) were used as markers for microglia; (O) HFA from one 17-week- old foetus (passaged once) - GFAP (Novocastra) merged with DAPI & CD11b (Novus); (P) HFA from an 18-week- old foetus (passaged once) - GFAP (DAKO) merged with DAPI & CD68 (zoomed: 2.1× magnification); (O & P) GFAP (green & red) was used as an astrocyte marker & CD68 (red) & CD11b (green) were used as markers for microglia. Nuclei indicated by DAPI (blue) in all images. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0112945), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-40766_rabbit-polyclonal-cd11b-c-antibody-310202416235543.jpg)
![Immunocytochemistry/Immunofluorescence: CD34 Antibody (MEC 14.7) [NB600-1071] - CD34 antibody was tested in WEHI-3 cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red).](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunocytochemistry-Immunofluorescence-NB600-1071-img0003.jpg)
![Immunohistochemistry-Paraffin: CD34 Antibody (MEC 14.7) [NB600-1071] - Analysis of a FFPE tissue section of mouse small intestine using rat anti-mouse CD34 (clone MEC 14.7) at 1:100 dilution. The signal was developed using HRP-conjugated anti-rat secondary with DAB reagent which followed counterstaining of nuclei using hematoxylin. This antibody specifically labelled the endothelial cells in blood vessels located primarily in the sub-mucosa, and of that of the mucosa muscularis and the mucosal lacteal.](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunohistochemistry-Paraffin-NB600-1071-img0014.jpg)
![Flow Cytometry: CD34 Antibody (MEC 14.7) [NB600-1071] - CD34 (MEC 14.7) antibody was tested at 1:250 in WEHI-3 cells with DyLight 488 (green) alongside a matched isotype control (black).](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Flow-Cytometry-NB600-1071-img0002.jpg)
![Immunohistochemistry-Paraffin: CD34 Antibody (MEC 14.7) [NB600-1071] - Analysis of CD34 on human renal cancer xenograft using CD34 antibody (clone MEC 14.7). The antibody detected the endothelial cells in the tumor vasculature which are originating from the host (mouse).](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunohistochemistry-Paraffin-NB600-1071-img0005.jpg)
![Immunohistochemistry-Paraffin: CD34 Antibody (MEC 14.7) [NB600-1071] - Analysis of a human renal cancer tissue section using CD34 antibody (clone MEC 14.7) at 1:100 dilution. The antibody did not detect human CD34 which is an expected outcome for this clone. This section was included in NB600-1071's IHC validation testing as a negative control.](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunohistochemistry-Paraffin-NB600-1071-img0006.jpg)
![Immunohistochemistry-Paraffin: CD34 Antibody (MEC 14.7) [NB600-1071] - Analysis of a FFPE tissue section of human renal cancer xenograft using CD34 antibody clone MEC 14.7 at 1:100 dilution. The signal was developed using HRP-conjugated secondary antibody and DAB reagent followed by counterstaining of nuclei with hematoxylin. Notably, the antibody specifically stained the endothelial cells of the tumor vasculature which is originating from the host animal cells (mouse). This observation was verified by including a negative control in this validation testing (see the IHC image of human renal cancer tissue section with negative signal for CD34).](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunohistochemistry-Paraffin-NB600-1071-img0009.jpg)
![Immunohistochemistry-Paraffin: CD34 Antibody (MEC 14.7) [NB600-1071] - Analysis of a FFPE tissue section of human renal cancer xenograft using CD34 antibody (clone MEC 14.7) at 1:100 dilution. The staining was detected using HRP-conjugated secondary antibody and DAB reagent followed by counterstaining of nuclei with hematoxylin. Note that this murine CD34 specific antibody stained only the endothelial cells of the tumor vasculature which is originating from the host animal cells (mouse). This observation was verified by including a negative control in this validation testing (see the IHC image of human renal cancer tissue section with negative signal for CD34).](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunohistochemistry-Paraffin-NB600-1071-img0010.jpg)
![Immunohistochemistry-Paraffin: CD34 Antibody (MEC 14.7) [NB600-1071] - Analysis of a FFPE tissue section of mouse colon using rat anti-mouse CD34 (clone MEC 14.7) at 1:100 dilution. The signal was developed using HRP-conjugated anti-rat secondary with DAB reagent which followed counterstaining of nuclei using hematoxylin. The antibody specifically generated a staining of the endothelial cells in blood vessels of the colon.](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunohistochemistry-Paraffin-NB600-1071-img0012.jpg)
![Immunohistochemistry-Paraffin: CD34 Antibody (MEC 14.7) [NB600-1071] - Analysis of a FFPE tissue section of mouse heart using rat anti-mouse CD34 (clone MEC 14.7) at 1:100 dilution. The signal was developed using HRP-conjugated anti-rat secondary with DAB reagent which followed counterstaining of nuclei using hematoxylin. The antibody specifically generated a staining of the endothelial cells in blood vessels of the heart tissue.](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunohistochemistry-Paraffin-NB600-1071-img0013.jpg)
![Flow Cytometry: CD34 Antibody (MEC 14.7) [NB600-1071] - An intracellular stain was performed on Raw264.7 cells with CD34 Antibody [MEC 14.7] NB600-1071 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rat IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 488 (SA5-10018, Thermo Fisher).](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Flow-Cytometry-NB600-1071-img0015.jpg)
![Western Blot: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Analysis using MCP1 mouse mAb against A549 (1), HeLa (2), Raw264.7 (3), L1210 (4), C6 (5), and COS-7 (6) cell lysates.](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Western-Blot-NBP2-22115-img0003.jpg "Western Blot: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Analysis using MCP1 mouse mAb against A549 (1), HeLa (2), Raw264.7 (3), L1210 (4), C6 (5), and COS-7 (6) cell lysates.")
![Immunocytochemistry/Immunofluorescence: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Analysis of HepG2 cells using A) MCP1 mAb (green), DRAQ5 fluorescent DNA dye (blue), and Actin filaments have been labeled with Alexa Fluor-555 phalloidin (red). B) Staining without MCP1 mAb](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Immunocytochemistry-Immunofluorescence-NBP2-22115-img0011.jpg)
![Immunohistochemistry: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - HER2 activates NF-kB and upregulates CCL2. MGs from FVB wild-type and 22-week-old MMTV-HER2 mice stained against CCL2, HER2, and CCR2. Bars: 25 um. Inset, CCR2 signal, zoom factor 1x; full image in Supplementary Fig. 5i. CCL2 intensity was quantified using ROI tool in Metamorph (Supplementary Fig. 5h). Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41467-017-02481-5), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Immunohistochemistry-NBP2-22115-img0009.jpg)
![Flow Cytometry: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Analysis of A549 cells using MCP1 mouse mAb (green) and negative control (red).](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Flow-Cytometry-NBP2-22115-img0004.jpg)
![Western Blot: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Analysis using MCP1 mAb against human MCP1 (AA: 1-99) recombinant protein. (Expected MW is 36.5 kDa)](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Western-Blot-NBP2-22115-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - CCL2 staining in acini cultures from MMTV-HER2 MGs (20-24 weeks) grown for 5 days and then DMSO-treated (vehicle control, e), 1uM lapatinib (f) or 1 uM IKKi compound A (g) for 24 hrs. Bar: 25 um. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41467-017-02481-5), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Immunocytochemistry-Immunofluorescence-NBP2-22115-img0010.jpg)
![<b>Biological Strategies Validation. </b>Immunohistochemistry: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Organotypic specimens were treated with anti-LIF for 72 h and then cultured with PBMCs for 24 h. CXCL9 and CCL2 mRNA expression levels are shown. Representative images (patient 4, 5, 6) of CFSE-stained PBMCs into Matrigel containing GBM specimens and IF of the indicated factors in organotypic tissues are displayed. Bars represent quantification of five different fields of each condition. Data are presented as mean +/- SD. Scale bar, 20 um. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31186412/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Immunohistochemistry-NBP2-22115-img0012.jpg)
![Immunohistochemistry-Paraffin: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Analysis of paraffin-embedded liver cancer tissues using MCP1 mouse mAb with DAB staining.](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Immunohistochemistry-Paraffin-NBP2-22115-img0007.jpg)
![ELISA: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Red: Control Antigen (100ng), Purple: Antigen (10ng), Green: Antigen (50ng), Blue: Antigen (100ng).](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-ELISA-NBP2-22115-img0001.jpg)
![Immunocytochemistry/ Immunofluorescence: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Expression patterns of CCL2 & CCR2 in unwounded & wounded corneas of WT & MMP12 KO mice. (A) Immunofluorescence of CCL2 chemokine & (B) its receptor CCR2 in unwounded & chemically wounded (2-days after injury) WT & Mmp12−/− mouse corneas. Control images represent mouse corneas stained with secondary antibody only & without primary antibody. Nuclei were visualized by staining with DAPI (blue). Scale bars: 50 µm. A magnified image of a wounded WT cornea shows perinuclear expression of CCL2 (orange box). CCL2 staining was visualized in epithelial, stromal, & endothelial layers of wounded WT & Mmp12−/− corneas. CCR2 staining was visualized in epithelial & stromal layers of unwounded & wounded WT & Mmp12−/− corneas. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31399604), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-22115_mouse-monoclonal-ccl2-mcp1-antibody-2d8-310202415384136.jpg)
![Immunocytochemistry/ Immunofluorescence: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - LIF represses CXCL9 through epigenetic silencing. a, b qRT-PCR analysis of the indicated genes in BMDMs. BMDMs were pre-incubated with 20 ng/ml LIF for 72 h & then stimulated with 5 ng/ml IFN gamma or 10 μg/ml IL4 during 6 h (a) or with 0.1, 0.5, 1 & 5 ng/ml IFN gamma for 24 h (b). c CXCL9 ELISA from BMDMs pre-incubated with 20 ng/ml LIF & then stimulated with 0.1 ng/ml IFN gamma for 24 h. d CXCL9 ELISA from human CD11b+sorted cells (77% CD11b+ CD14+, see Supplementary Fig. 7b, c) from human GBM cultured with 20 ng/ml LIF for 72 h & then with 0.1 ng/ml IFN gamma for 24 h. e ChIP of Tri-methyl-histone H3 (H3K27me3), EZH2 & acetyl-histone4 (H4ac) was performed in BMDMs treated with 20 ng/ml LIF for 72 h. Scheme shows the analysed CXCL9 promoter region. Representative data are presented as mean ± SD. f Representative images of IF of the indicated markers in human GBM organotypic slices (patients 1, 2, 3) incubated with 10 μg/ml anti-LIF for 3 days. Scale bar, 20 μm. (see Supplementary Fig. 8). Bottom, percentage of double positive cells relative to Iba1+ cells & percentage of CXCL9+ cells relative to the total number of cells. Data are mean of all patients ± SEM. Statistical analyses by Student’s t-test or Mann–Whitney T-test. *P < 0.05, **P < 0.01; ***P < 0.001; ****P < 0.0001 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31186412), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-22115_mouse-monoclonal-ccl2-mcp1-antibody-2d8-3102024161360.jpg)
![Immunohistochemistry: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - LIF regulates CXCL9, CCL2, CD206, & CD163 in TAMs. a Differential expression analysis of isolated CD11b+ cells from anti-LIF treated ID8 mice vs. control. Volcano plot representing the genes significantly (Q-value < 0.1) overexpressed (brown) & significantly underexpressed (turquoise). Heatmap representing the expression values of the indicated genes, each column represents a sample & each row a gene. The last column represents the log2 fold change (log2 FC) of gene expression. b mRNA expression for the indicated genes in isolated CD11b+ cells from anti-LIF treated or untreated ID8 & GL261N tumors. c Percentage & mean fluorescence intensity (MFI) of CCL2 & CXCL9 in TAMs (CD11b+ Ly6G− Ly6C−) from anti-LIF treated or untreated GL261N tumors. d Representative IF images of Iba1 & the indicated markers stainings of GL261N tumors (see Supplementary Fig. 4). Scale bar, 20 μm. Bottom, percentage of double positive cells relative to the TAM marker positive cells. CXCL9 quantification is relative to the total number of cells. e Tumor growth of GL261N in WT, CXCL9−/−, & CCL2−/− mice or mice treated with the indicated antibodies is shown as total flux (p/s). f Fold change (FC) of tumor infiltrating CD8+ T cells in the indicated treatments. Data are mean ± SEM. g, h Representative IHC of the indicated markers from 20 GBM tumors. The degree of staining was quantified using H-score method. Correlations between LIF & CCL2, CD206, CD163, & CXCL9 with the R-squared coefficients (R2) were calculated (h). Statistical analyses by Mann–Whitney T-test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31186412), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-22115_mouse-monoclonal-ccl2-mcp1-antibody-2d8-310202416114760.jpg)
![Immunocytochemistry/ Immunofluorescence: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - LIF regulates CXCL9, CCL2, CD206, & CD163 in TAMs. a Differential expression analysis of isolated CD11b+ cells from anti-LIF treated ID8 mice vs. control. Volcano plot representing the genes significantly (Q-value < 0.1) overexpressed (brown) & significantly underexpressed (turquoise). Heatmap representing the expression values of the indicated genes, each column represents a sample & each row a gene. The last column represents the log2 fold change (log2 FC) of gene expression. b mRNA expression for the indicated genes in isolated CD11b+ cells from anti-LIF treated or untreated ID8 & GL261N tumors. c Percentage & mean fluorescence intensity (MFI) of CCL2 & CXCL9 in TAMs (CD11b+ Ly6G− Ly6C−) from anti-LIF treated or untreated GL261N tumors. d Representative IF images of Iba1 & the indicated markers stainings of GL261N tumors (see Supplementary Fig. 4). Scale bar, 20 μm. Bottom, percentage of double positive cells relative to the TAM marker positive cells. CXCL9 quantification is relative to the total number of cells. e Tumor growth of GL261N in WT, CXCL9−/−, & CCL2−/− mice or mice treated with the indicated antibodies is shown as total flux (p/s). f Fold change (FC) of tumor infiltrating CD8+ T cells in the indicated treatments. Data are mean ± SEM. g, h Representative IHC of the indicated markers from 20 GBM tumors. The degree of staining was quantified using H-score method. Correlations between LIF & CCL2, CD206, CD163, & CXCL9 with the R-squared coefficients (R2) were calculated (h). Statistical analyses by Mann–Whitney T-test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31186412), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-22115_mouse-monoclonal-ccl2-mcp1-antibody-2d8-31020241613617.jpg)
![Simple Western: 15-PGDH/HPGD Antibody [NB200-179] - Simple Western lane view shows a specific band for 15-PGDH/HPGD in 0.5 mg/ml of Lovo (left) and HeLa (right) lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/15-PGDH-HPGD-Antibody-Simple-Western-NB200-179-img0005.jpg "Simple Western: 15-PGDH/HPGD Antibody [NB200-179] - Simple Western lane view shows a specific band for 15-PGDH/HPGD in 0.5 mg/ml of Lovo (left) and HeLa (right) lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.")
![Immunohistochemistry: 15-PGDH/HPGD Antibody [NB200-179] - Expression of 15-prostaglandin dehydrogenase (15-PGDH) in healthy and inflamed synovial tissue. Immunohistochemical staining reveals positive (brown) staining for 15-PGDH (hematoxilin counterstained) in synovial tissue from healthy individuals (a) and patients with rheumatoid arthritis (b), osteoarthritis (c), or psoriatic arthritis (d). Original magnifications: x250 (a, b), x100 (c, d). Image collected and cropped by CiteAb from the following publication (//arthritis-research.biomedcentral.com/articles/10.1186/ar3851), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/15-PGDH-HPGD-Antibody-Immunohistochemistry-NB200-179-img0015.jpg)
![Immunohistochemistry: 15-PGDH/HPGD Antibody [NB200-179] - Cellular localization of 15-prostaglandin dehydrogenase (15-PGDH/HPGD) in rheumatoid arthritis synovial tissue and the effects of anti-rheumatic treatment on its expression. Double-immunofluorescence images show staining for 15-PGDH/HPGD-positive (red) cells and cell marker staining (green) for macrophage CD163, fibroblast prolyl-4-hydroxylase, and endothelial cell CD31. Merged images display double-stained cells in yellow. Original magnification: x400. Image collected and cropped by CiteAb from the following publication (//arthritis-research.biomedcentral.com/articles/10.1186/ar3851), licensed under a CC-BY license](http://images.novusbio.com/fullsize/15-PGDH-HPGD-Antibody-Immunohistochemistry-NB200-179-img0016.jpg)
![Western Blot: 15-PGDH/HPGD Antibody [NB200-179] - Western blot analysis of 15-PGDH in Lovo cell lysate.](http://images.novusbio.com/fullsize/15-PGDH-HPGD-Antibody-Western-Blot-NB200-179-img0001.jpg)
![Immunocytochemistry/Immunofluorescence: 15-PGDH/HPGD Antibody [NB200-179] - Confocal microscopy immunofluorescence images showing the expression of 15-PGDH (in green; antibody dilution, 1:200; DAPI in blue) after 24 h of stimulation with LTC4 in Caco-2 cells. The objective used was 63x. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28402256/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/15-PGDH-HPGD-Antibody-Immunocytochemistry-Immunofluorescence-NB200-179-img0017.jpg)
![Immunocytochemistry/Immunofluorescence: 15-PGDH/HPGD Antibody [NB200-179] - 15-PGDH antibody was tested in HeLa cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/15-PGDH-HPGD-Antibody-Immunocytochemistry-Immunofluorescence-NB200-179-img0004.jpg)
![Immunohistochemistry-Paraffin: 15-PGDH/HPGD Antibody [NB200-179] - IHC analysis of 15-PGDH in human synovial tissue from patient with rheumatoid arthritis . Image courtesy of an anonymous customer review.](http://images.novusbio.com/fullsize/15-PGDH-HPGD-Antibody-Immunohistochemistry-Paraffin-NB200-179-img0003.jpg)
![Immunohistochemistry: 15-PGDH/HPGD Antibody [NB200-179] - Staining in human fetal membrane tissue. Image from verified customer review.](http://images.novusbio.com/fullsize/15-PGDH-HPGD-Antibody-Immunohistochemistry-NB200-179-img0009.jpg)
![<b>Biological Strategies Validation and Genetic Strategies Validation.</b>Western Blot: 15-PGDH/HPGD Antibody [NB200-179] - A representative western blot and densitometric analysis of LTC4-induced SI protein expression after transfection with a scrambled control siRNA or 15-PGDH siRNA in HT-29 cells are shown. The cells were treated with or without 40 nM LTC4 for 48 h, and the change in the SI protein level was detected using an SI-specific antibody (1:1000 dilution) and 15-PGDH was detected using a 15-PGDH antibody (1:5000 dilution). The membrane was re-probed with an antibody against beta-actin to ensure equal loading. Statistical analysis was conducted using an unpaired t-test; *P=0.05, **P<0.01. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28402256/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/15-PGDH-HPGD Antibody-Knockdown Validated-NB200-179-img0018.jpg)
![Immunohistochemistry: 15-PGDH/HPGD Antibody [NB200-179] - Expression of 15-prostaglandin dehydrogenase (15-PGDH) in healthy & inflamed synovial tissue. Immunohistochemical staining reveals positive (brown) staining for 15-PGDH (hematoxilin counterstained) in synovial tissue from healthy individuals (a) & patients with rheumatoid arthritis (b), osteoarthritis (c), or psoriatic arthritis (d). Original magnifications: ×250 (a, b), ×100 (c, d). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/22616846), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-179_rabbit-polyclonal-15-pgdh-hpgd-antibody-310202415291984.jpg)
![Immunohistochemistry: 15-PGDH/HPGD Antibody [NB200-179] - Expression of 15-prostaglandin dehydrogenase (15-PGDH) in healthy & inflamed synovial tissue. Immunohistochemical staining reveals positive (brown) staining for 15-PGDH (hematoxilin counterstained) in synovial tissue from healthy individuals (a) & patients with rheumatoid arthritis (b), osteoarthritis (c), or psoriatic arthritis (d). Original magnifications: ×250 (a, b), ×100 (c, d). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/22616846), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-179_rabbit-polyclonal-15-pgdh-hpgd-antibody-310202415384117.jpg)
![Immunohistochemistry: 15-PGDH/HPGD Antibody [NB200-179] - Expression of 15-prostaglandin dehydrogenase (15-PGDH) in healthy & inflamed synovial tissue. Immunohistochemical staining reveals positive (brown) staining for 15-PGDH (hematoxilin counterstained) in synovial tissue from healthy individuals (a) & patients with rheumatoid arthritis (b), osteoarthritis (c), or psoriatic arthritis (d). Original magnifications: ×250 (a, b), ×100 (c, d). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/22616846), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-179_rabbit-polyclonal-15-pgdh-hpgd-antibody-31020241539722.jpg)
![Immunohistochemistry: 15-PGDH/HPGD Antibody [NB200-179] - Expression of 15-prostaglandin dehydrogenase (15-PGDH) in healthy & inflamed synovial tissue. Immunohistochemical staining reveals positive (brown) staining for 15-PGDH (hematoxilin counterstained) in synovial tissue from healthy individuals (a) & patients with rheumatoid arthritis (b), osteoarthritis (c), or psoriatic arthritis (d). Original magnifications: ×250 (a, b), ×100 (c, d). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/22616846), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-179_rabbit-polyclonal-15-pgdh-hpgd-antibody-310202415291976.jpg)
![Immunocytochemistry/ Immunofluorescence: 15-PGDH/HPGD Antibody [NB200-179] - Cellular localization of 15-prostaglandin dehydrogenase (15-PGDH) in rheumatoid arthritis synovial tissue & the effects of anti-rheumatic treatment on its expression. (a) Double-immunofluorescence images show staining for 15-PGDH-positive (red) cells & cell marker staining (green) for macrophage CD163, fibroblast prolyl-4-hydroxylase, & endothelial cell CD31. Merged images display double-stained cells in yellow. Original magnification: ×400. Light microscopy pictures of representative synovial biopsy sections show immunohistochemical positive (brown) staining for 15-PGDH before & after intra-articular treatment with glucocorticoids (b) & before & 8 weeks after initiation of methotrexate therapy (c) (hematoxilin counterstained). Graphs display the comparative 15-PGDH expression in rheumatoid arthritis synovial tissue before & after treatment with glucocorticoids or methotrexate as a percentage of the positive stained area versus the total tissue area. GC, glucocorticoids; Mtx, methotrexate. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/22616846), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-179_rabbit-polyclonal-15-pgdh-hpgd-antibody-31020241621232.jpg)
![Western Blot: 15-PGDH/HPGD Antibody [NB200-179] - Effect of LTC4 on 15-PGDH expression in the colon cancer cell line Caco-2(A) Quantification by qPCR of the mRNA expression of 15-PGDH following treatment with 40 nM LTC4 for 48 h in the presence or absence of AP100984 (a CysLT2 receptor antagonist, 1 μM) & JNK inhibitor I (10 μM). (B) Western blot showing 15-PGDH expression (antibody dilution, 1:5000) & densitometric analysis of LTC4-induced 15-PGDH up-regulation before or after the cells were stimulated with 40 nM LTC4 in the presence or absence of AP100984 & JNK inhibitor I for 48 h. (C) Confocal microscopy immunofluorescence images showing the expression of 15-PGDH (in green; antibody dilution, 1:200; DAPI in blue) after 24 h of stimulation with LTC4 in Caco-2 cells. The objective used was 63x. The data are presented as the percent of untreated control cells & represent the mean ± SEM of at least three separate experiments. Statistical analysis was conducted using an unpaired t-test; *P≤0.05, **P<0.01, ***P<0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28402256), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-179_rabbit-polyclonal-15-pgdh-hpgd-antibody-310202416205174.jpg)
![Western Blot: 15-PGDH/HPGD Antibody [NB200-179] - Effect of 15-PGDH down-regulation on the cell differentiation markers SI & Mucin-2(A) A representative western blot & densitometric analysis of LTC4-induced SI protein expression after transfection with a scrambled control siRNA or 15-PGDH siRNA in HT-29 cells are shown. The cells were treated with or without 40 nM LTC4 for 48 h, & the change in the SI protein level was detected using an SI-specific antibody (1:1000 dilution) & 15-PGDH was detected using a 15-PGDH antibody (1:5000 dilution). The membrane was re-probed with an antibody against beta –actin to ensure equal loading. (B) A representative western blot & densitometric analysis performed as in (A) shown here for Caco-2 cells. (C, D) Representative confocal microscopy immunofluorescence images from cells transfected with a scrambled control siRNA or 15-PGDH siRNA with or without stimulation with 40 nM LTC4 for 48 h. The expression of Mucin-2 (in red; antibody dilution, 1:500; DAPI in blue, dilution 1:1000) (C) in HT-29 cells & (D) Caco-2 cells is shown. The objective used was 63x, & the scale bar is 50 μm. The data are presented as the percent of control cells & represent the mean ± SEM of at least three separate experiments. Statistical analysis was conducted using an unpaired t-test; *P≤0.05, **P<0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28402256), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-179_rabbit-polyclonal-15-pgdh-hpgd-antibody-310202416212329.jpg)
![Immunohistochemistry: 15-PGDH/HPGD Antibody [NB200-179] - Cellular localization of 15-prostaglandin dehydrogenase (15-PGDH) in rheumatoid arthritis synovial tissue & the effects of anti-rheumatic treatment on its expression. (a) Double-immunofluorescence images show staining for 15-PGDH-positive (red) cells & cell marker staining (green) for macrophage CD163, fibroblast prolyl-4-hydroxylase, & endothelial cell CD31. Merged images display double-stained cells in yellow. Original magnification: ×400. Light microscopy pictures of representative synovial biopsy sections show immunohistochemical positive (brown) staining for 15-PGDH before & after intra-articular treatment with glucocorticoids (b) & before & 8 weeks after initiation of methotrexate therapy (c) (hematoxilin counterstained). Graphs display the comparative 15-PGDH expression in rheumatoid arthritis synovial tissue before & after treatment with glucocorticoids or methotrexate as a percentage of the positive stained area versus the total tissue area. GC, glucocorticoids; Mtx, methotrexate. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/22616846), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-179_rabbit-polyclonal-15-pgdh-hpgd-antibody-310202416205129.jpg)